Osteoporosis and inflammatory bowel disease

Authors

  • C. N. Bernstein,

    1. University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, and Manitoba Osteoporosis Programme, Winnipeg, Man., Canada
    Search for more papers by this author
  • W. D. Leslie

    1. University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, and Manitoba Osteoporosis Programme, Winnipeg, Man., Canada
    Search for more papers by this author

Professor C. N. Bernstein, Section of Gastroenterology, University of Manitoba, 804F-715 McDermot Avenue, Winnipeg, Man., Canada R3E 3P4.
E-mail: cbernst@cc.umanitoba.ca

Summary

Studies using dual-energy X-ray absorptiometry have suggested a high prevalence of osteoporosis in inflammatory bowel disease. However, population-based data on fracture incidence suggest only a small increased risk of fracture amongst patients with inflammatory bowel disease compared with the general population. Therefore, it would be helpful to identify patients with inflammatory bowel disease at particularly high risk for fracture so that these risks might be modified or interventions might be undertaken. The data on calcium intake as a predictor of bone mineral density are conflicting. Although there are data suggesting that a one-time survey to determine current calcium intake will not help to predict bone mineral density in inflammatory bowel disease, persistently reduced calcium intake does appear to lead to lower bone mineral density. In the general population, body mass is strongly correlated with bone mineral density, which also appears to be true in Crohn's disease. Hence, subjects with inflammatory bowel disease and considerable weight loss, or who are obviously malnourished, could be considered for bone mineral density testing, and the finding of a low bone mineral density would suggest the need for more aggressive nutritional support. Although vitamin D is undoubtedly important in bone health, vitamin D intake and serum vitamin D levels do not correlate well with bone mineral density. Sex hormone deficiency can also adversely affect bone health, although a well-developed strategy for sex hormone measurements in patients with inflammatory bowel disease remains to be established. Ultimately, the determination of genetic mutations that accurately predict fracture susceptibility may be the best hope for developing a simplified strategy for managing bone health in inflammatory bowel disease.

The therapy of osteoporosis in inflammatory bowel disease has been adapted from other osteoporosis settings, such as post-menopausal or corticosteroid-induced osteoporosis. To date, there remains no therapy proven to be efficacious in inflammatory bowel disease-related osteoporosis; however, calcium and vitamin D supplementation and bisphosphonates have their roles.

Ancillary